Grifols, S.A. (VIE:GRF)
Austria · Delayed Price · Currency is EUR | Market Cap | 5.55B +7.9% |
| Revenue (ttm) | 7.44B +0.9% |
| Net Income | 415.00M +112.6% |
| EPS | 0.61 |
| Shares Out | n/a |
| PE Ratio | 13.39 |
| Forward PE | 8.55 |
| Dividend | 0.12 (1.33%) |
| Ex-Dividend Date | Aug 11, 2025 |
| Volume | n/a |
| Average Volume | n/a |
| Open | 8.98 |
| Previous Close | 8.91 |
| Day's Range | 8.79 - 8.98 |
| 52-Week Range | 8.08 - 13.60 |
| Beta | n/a |
| RSI | 39.59 |
| Earnings Date | May 7, 2026 |
About Grifols
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as wel... [Read more]
Financial Performance
In 2025, Grifols's revenue was 7.52 billion, an increase of 4.33% compared to the previous year's 7.21 billion. Earnings were 402.00 million, an increase of 156.05%.
Financial StatementsNews
Q1 2026 Grifols SA Earnings Call Transcript
Q1 2026 Grifols SA Earnings Call Transcript
Grifols reports Q1 adjusted EBITDA EUR 381M, up 0.8% cc
Reports Q1 total revenue EUR 1.7B, up 3.3% y/y cc. Group profit increased to EUR 73M in the first quarter, up 21.9% year-on-year. Nacho Abia, CEO of Grifols (GRFS), said:
Grifols says Q1 results support FY26 guidance
11:43 EDT Grifols (GRFS) says Q1 results support FY26 guidance
Grifols Q1 Profit Rises
(RTTNews) - Plasma-derived medicines company Grifols S.A. (GRFS) on Thursday reported higher first-quarter profit and revenue, driven by continued strong demand for immunoglobulin therapies and growth...
New conditions imposed on Grifols by Health Canada, CBC News reports
Health Canada has imposed new terms and conditions on all of Grifols (GRFS)’ paid plasma centers following multiple failed inspections that identified recurring systemic deficiencies, including inadeq...
Ban Grifols and return plasma collection to Canadian Blood Services and Héma-Québec, say health care advocates
OTTAWA, March 30, 2026 (GLOBE NEWSWIRE) -- Proponents of public universal health care across Canada are calling for the closure of Grifols facilities in the wake of two deaths in Winnipeg of people wh...
Grifols rallies after board approves IPO of U.S. Biopharma business
Grifols (GRFS) says its Strategy Committee has proposed, and the board has approved, the initial public offering on the U.S. stock market of a portion of the shares of the
Grifols to evaluate potential IPO of U.S. Biopharma business
According to a regulatory filing, Grifols (GRFS) reported that, as a consequence of Grifols’ self-sufficiency programs for its Biopharma businesses, its Board of Directors has decided to initiate a pr...
Grifols approves IPO of its US biopharma business
Healthcare company Grifols said on Tuesday it has approved a U.S. initial public offering of its U.S. biopharma business.
Grifols price target lowered to EUR 11 from EUR 12 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Grifols (GRFS) to EUR 11 from EUR 12 and keeps a Hold rating on the shares.
Grifols shares results of Chronos Platforms identifying early Parkinson’s
Grifols (GRFS) shared proof-of-concept data from its Chronos-PD program, demonstrating that biological changes in individuals with Parkinson’s disease occur more than a decade before clinical diagnosi...
Grifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with Parkinson's Disease
BARCELONA, Spain, March 17, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today shared proof-of-conc...
Health Coalition demands disclosures & end to Grifols' for-profit blood plasma contract following reports of deaths, harm, non-compliance
TORONTO, March 13, 2026 (GLOBE NEWSWIRE) -- The Ontario and Manitoba Health Coalitions held a press conference this morning to respond to a report from CBC about two patients who died in Winnipeg af...
Media Advisory: Press Conference Regarding Tragic Deaths After Plasma Harvesting at Grifols' Sites
WINNIPEG, Manitoba and TORONTO, March 12, 2026 (GLOBE NEWSWIRE) -- What: Spokespeople from the Manitoba Health Coalition and Ontario Health Coalition will respond to the sad news of two deaths of paid...
Grifols downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley downgraded Grifols (GRFS) to Equal Weight from Overweight with a price target of EUR 11, down from EUR 14. The firm cites uncertainties around the company’s revenue growth
Grifols doubles net profit in 2025, driven by revenues
Spanish drugmaker Grifols reported on Thursday a net profit of 402 million euros ($473.96 million) for 2025, more than double what it recorded the previous year, driven by revenues of 7.5 billion euro...
Grifols reports Q4 adjusted EBITDA EUR 467M, consensus EUR 469.7M
Reports Q4 revenue EUR 1.98B, consensus EUR 1.95B. The company said, “We are confident about Grifols (GRFS)’ highly differentiated strategy and positioning, which has been many years in the making
Grifols sees 2026 adjusted EBITDA growth 5%-9%
The company said, “For 2026, Grifols (GRFS) expects reaching Free Cash Flow pre-M&A pre-dividends of EUR 500m-575m, an Adjusted EBITDA margin of greater than or equal to25% with continued Adjusted
Grifols price target lowered to EUR 13.50 from EUR 15 at Barclays
Barclays lowered the firm’s price target on Grifols (GRFS) to EUR 13.50 from EUR 15 and keeps an Overweight rating on the shares.
Grifols price target lowered to EUR 8.50 from EUR 9 at JPMorgan
JPMorgan lowered the firm’s price target on Grifols (GRFS) to EUR 8.50 from EUR 9 and keeps a Neutral rating on the shares.
Grifols price target lowered to $10 from $10.30 at JPMorgan
JPMorgan lowered the firm’s price target on Grifols (GRFS) to $10 from $10.30 and keeps a Neutral rating on the shares. The firm adjusted ratings and targets in the European
Grifols reports Q3 adjusted EBITDA of EUR 482M, up 8.8% in constant currency
Revenues for the quarter totaled EUR 1,865B, increasing by 9.1% in constant currency year-over-year, driven by the Biopharma business. Nacho Abia, CEO of Grifols (GRFS), said: “Grifols maintains momen...
Spanish court summons Gotham City founder in Grifols share price probe
Spain's High Court on Thursday summoned the founder of U.S.-based short seller Gotham City Research, Daniel Yu, to testify over allegations his company disseminated misleading information about pharma...
Grifols price target raised to EUR 12 from EUR 10 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Grifols (GRFS) to EUR 12 from EUR 10 and keeps a Hold rating on the shares.
Grifols reports Q2 revenue EUR 1.89B vs. EUR 1.79B last quarter
Reports Q2 profit EUR 191M vs. EUR 115M last quarter. The company said, “The company’s strong performance in the first six months of 2025 reflects the solid execution of our